Paul Frewer
AstraZeneca, Melbourn Science Park
Melbourn, ENG, United Kingdom
Melbourn, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Journal: Cancer discovery
Published: May 31, 2022
Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in Oncology.
Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in Oncology.
Journal: Therapeutic innovation & regulatory science
Published: July 29, 2021
Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam.
Journal: British journal of clinical pharmacology
Published: April 12, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 06, 2021
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Journal: The Lancet. Oncology
Published: September 23, 2019
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 28, 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2017
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: December 23, 2015
Decision-making in early clinical drug development.
Journal: Pharmaceutical statistics
Published: June 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Journal: The New England journal of medicine
Published: April 30, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026